26 completed, 10 recruiting, 6 unknown, 3 terminated. 47 Phase 2, 13 Phase 1, 10 Phase 3.
Follow Palliative Care: new trials by email Literature Review of Palliative Care trials Research Report on Palliative Care
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Partner4Exercise Study Peer matching, Quailfied Exercise Professional (QEP) Support - Cancer | Phase 2 / Phase 3 | Recruiting | McMaster University | 183 | 2026-09-01 | 2026-10-29 |
| Psilocybin-Assisted Therapy psilocybin, Supportive Therapy, Prolonged Exposure Therapy - PTSD | Phase 2 | Recruiting | Emory University | 150 | 2026-06-08 | 2026-10-01 |
| Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive care - Non-Small Cell Lung Cancer, Advanced/Metastatic | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-06-11 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-01 |
| Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive Care - Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 48 | 2026-02-02 | 2026-03-12 |
| Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC Dual-target CAR-NK cells, Lymphodepleting, Supportive care - Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-02-02 | 2026-04-06 |
| Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care - Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-02-02 | 2026-03-20 |
| Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease Exertional Oxygen, Education and Support - Fibrotic Interstitial Lung Disease | Phase 2 | Recruiting | University of Alberta | 60 | 2025-07-01 | 2026-11-05 |
| Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W Maximum TURBT, Chemotherapy + Immunotherapy Induction, Radiotherapy - Muscle-invasive Bladder Cancer | Phase 2 | Recruiting | American University of Beirut Medical Center | 80 | 2025-06-11 | 2026-10-29 |
| A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling - Long COVID, Post-Acute COVID-19 Syndrome | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2025-06-01 | 2025-08-26 | |
| Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy - Locally Advanced Colorectal Cancer, Postoperative Adjuvant Therapy | Phase 2 | Not yet recruiting | Sir Run Run Shaw Hospital | 80 | 2024-10-01 | 2024-09-19 |
| Enhancing Work Participation of Unemployed and Work-Disabled Cancer Survivors PLACES - Cancer Survivors, Return to Work | Phase 2 / Phase 3 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 164 | 2023-09-01 | 2023-09-29 |
| Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma Gemcitabine, supportive care - Malignant Pleural Mesothelioma | Phase 2 | Completed | Ain Shams University | 40 | 2023-04-01 | 2024-08-27 |
| The Use of Eltrombopag Post HSCT in BMFD Eltrombopag 25 MG Oral Tablet, Supportive care - Stem Cell Transplant Complications | Phase 2 / Phase 3 | Completed | The First Affiliated Hospital of Soochow University | 118 | 2022-10-22 | 2025-12-03 |
| AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission Azacitidine, Venetoclax, Supportive care - Acute Myeloid Leukemia (AML) in Remission | Phase 2 / Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 124 | 2022-06-25 | 2022-08-19 |
| Avatrombopag to Promote Platelet Engraftment After Allo-HSCT Avatrombopag, Supportive care - Platelet Disorder | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2021-12-01 | 2022-12-23 |
| Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma Standard therapy or clinical trial, Matched targeted therapy, Trametinib and / or supportive care - Melanoma | Phase 2 | Completed | Melanoma Institute Australia | 216 | 2021-11-22 | 2026-05-29 |
| Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) Mesenchymal Stromal Cells, Supportive Care - Sars-CoV2, Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 28 | 2021-02-12 | 2026-10-21 |
| Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants Zanubrutinib, Supportive Care, Placebo - COVID-19 Pulmonary Complications, COVID-19 | Phase 2 | Completed | BeiGene | 63 | 2020-07-06 | 2024-10-26 |
| Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients Convalescent Plasma Transfusion, Supportive Care, Random Donor Plasma - COVID | Phase 2 | Completed | Institute of Liver and Biliary Sciences, India | 29 | 2020-04-20 | 2020-06-12 |
Showing 20 of 47. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (3) · Depression (3) · Neoplasm Metastasis (3) · Stress Disorders, Post-Traumatic (3) · Thrombocytopenia (3) · Bipolar Disorder (2) · Breast Neoplasms (2) · COVID-19 (2) · Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Heart Failure (2) · Leukemia, Myeloid, Acute (2) · Mental Disorders (2) · Neoplasms (2) · Pain (2)
Beijing Biotech (5) · The First Affiliated Hospital of Soochow University (3) · King's College London (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Ain Shams University (1) · All India Institute of Medical Sciences (1) · American University of Beirut Medical Center (1) · Annie Im, M.D. (1) · Arizona State University (1) · Baylor College of Medicine (1) · BeiGene (1) · Beth Israel Deaconess Medical Center (1) · Brigham and Women's Hospital (1) · Centre Oscar Lambret (1) · Clifford Hospital, Guangzhou, China (1)
United States (17) · China (11) · Canada (2) · India (2) · Australia (1) · Bangladesh (1) · Brazil (1) · Denmark (1) · Egypt (1) · France (1) · Germany (1) · Kenya (1) · Lebanon (1) · Netherlands (1) · Singapore (1)
Abanoub Samir (1) · Alex Menzies (1) · Amy Mathews, M.D. (1) · Anna Wise, PhD (1) · Annie Im, MD (1) · Arthur J. Barsky, MD (1) · Brian Fallon, MD (1) · Depei Wu, PhD,MD (1) · Douglas W. Woods, PhD (1) · Elizabeth W. Twamley, PhD (1) · Helen Heslop, MD (1) · Irene J Higginson, BMBS FRCP FFPHM PhD (1) · James R. Rodrigue, PhD (1) · Jeffrey Cully, PhD MEd BS (1)
PMID 11174237, PMID 11309435, PMID 11837876, PMID 17058754, PMID 18215105, PMID 18507817, PMID 19833477, PMID 20358414, PMID 21411144, PMID 21978993, PMID 22868933, PMID 23024246, PMID 23130740, PMID 24001701, PMID 24144615, PMID 25187211, PMID 25271779, PMID 25988365, PMID 26423375, PMID 26631085, PMID 26763495, PMID 26785798, PMID 26908586, PMID 27724833, PMID 28069021, PMID 28202705, PMID 28606503, PMID 28659038, PMID 28846584, PMID 29029679, PMID 29316883, PMID 29480043, PMID 29590544, PMID 29729555, PMID 30790469, PMID 33002633, PMID 33178737, PMID 33987095, PMID 34013969, PMID 34376578, PMID 35522399, PMID 36734509, PMID 36856579, PMID 37142273, PMID 37162745, PMID 38258329, PMID 38330639, PMID 38761558, PMID 39252084, PMID 39906744
2009 (1), R01CA227092 (1), R01DK072325 (1), R01MH069877 (1), R01MH071688 (1), R01MH072591 (1), R01MH080150 (1), R01MH080966 (1), R21DK077322 (1)